Kamada (KMDA) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12-month price targets for Kamada's shares. Their KMDA share price forecasts range from $11.00 to $11.00. On average, they anticipate the company's share price to reach $11.00 in the next year. This suggests a possible upside of 127.7% from the stock's current price.
View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts.

Kamada's stock was trading at $4.01 at the beginning of the year. Since then, KMDA stock has increased by 20.4% and is now trading at $4.83.
View the best growth stocks for 2023 here.

Kamada saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 5,400 shares, a decrease of 60.6% from the April 30th total of 13,700 shares. Based on an average trading volume of 20,300 shares, the short-interest ratio is currently 0.3 days. Currently, 0.0% of the shares of the stock are sold short.
View Kamada's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 16th 2023.
View our KMDA earnings forecast.

Kamada Ltd. (NASDAQ:KMDA) issued its quarterly earnings data on Wednesday, March, 15th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $0.04. The biotechnology company had revenue of $45.44 million for the quarter, compared to the consensus estimate of $44.64 million. Kamada had a positive trailing twelve-month return on equity of 8.15% and a negative net margin of 1.74%.

Kamada updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $141.36 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW).

Kamada trades on the NASDAQ under the ticker symbol "KMDA."

Kamada's stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.89%), Acadian Asset Management LLC (1.44%), Altshuler Shaham Ltd (0.79%), Meitav Investment House Ltd. (0.15%) and UBS Group AG (0.11%).

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KMDA stock can currently be purchased for approximately $4.83.

Kamada (NASDAQ:KMDA) has a market capitalization of $216.48 million and generates $129.34 million in revenue each year. The biotechnology company earns $-2,320,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.

The company employs 355 workers across the globe.

Kamada's mailing address is 2 HOLTZMAN ST. SCIENCE PARK, REHOVOT L3, 7670402. The official website for the company is www.kamada.com. The biotechnology company can be reached via phone at (728) 940-6472, via email at ir@kamada.com, or via fax at 972-8940-6473.